A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate
- 1 September 1983
- Vol. 52 (5) , 856-860
- https://doi.org/10.1002/1097-0142(19830901)52:5<856::aid-cncr2820520519>3.0.co;2-4
Abstract
A Newcastle disease virus lysate of malignant melanoma cells was examined for its possible value in delaying the progression of malignant melanoma with palpable regional node disease (Stage II) to disseminated melanoma (Stage III). This Phase II study was carried out in a group of 32 patients following therapeutic lymphadenectomy. The patients were not prospectively randomized. In each patient, the viral oncolysate was administered subcutaneously at regular intervals over 3 years. The cumulated progressions to disseminated disease at 1, 2 and 3 years were 6%, 8% and 12% of the study group, respectively. These experienced losses were considerably lower than in the control group and in similar control groups described by other investigators. The results suggest that an oncolysate prepared with Newcastle disease virus is a helpful adjunct to surgery in the management of Stage II malignant melanoma.This publication has 24 references indexed in Scilit:
- Prognostic Factors for Patients with Clinical Stage I Melanoma of Intermediate Thickness (1.51–3.99 mm)* A Conceptual Model for Tumor Growth and MetastasisAnnals of Surgery, 1982
- Prognostic Factors for Melanoma Patients with Lesions 0.76–1.69 mm in Thickness An Appraisal of “Thin” Level IV LesionsAnnals of Surgery, 1982
- A Multivariate Analysis of Prognostic Factors for Melanoma Patients with Lesions > 3.65 mm in Thickness The Importance of Revealing Alternative Cox Models*Annals of Surgery, 1982
- A Multifactorial Analysis of MelanomaAnnals of Surgery, 1981
- Selective Surgical Management of Cutaneous Melanoma of the Head and NeckAnnals of Surgery, 1980
- Adjuvant Immunotherapy with BCG in Treatment of Regional-Lymph-Node Metastases from Malignant MelanomaNew England Journal of Medicine, 1976
- Melanoma Antigens That Produce Cell-Mediated Immune Responses in Melanoma Patients: Joint U.S.-U.S.S.R. StudyScience, 1975
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973
- Immunological Aspects of Neoplasia: A Rational Basis for ImmunotherapyAnnals of Internal Medicine, 1971
- A simple method for determining standard errors of survival rates, with tablesJournal of Chronic Diseases, 1960